Implication de l'IL-26 dans la sclérose en plaques


Evelyn Peelen

Centre de recherche du Centre hospitalier de l'Université de Montréal


Domaine : maladies infectieuses et immunitaires

Programme Formation postdoctorale (CITOYENS D'AUTRES PAYS)

Concours 2018-2019

Partenaire :

Société canadienne de la sclérose en plaques

Multiple sclerosis (MS) affects more than 2.5 million people worldwide and has a tremendous impact on their quality of life. It is a detrimental disease with symptoms ranging from visual problems to muscle weakness which results in walking problem and eventually becoming a wheelchair user. In MS, the body's own defense system enters and attacks the brain, which does not occur in healthy individuals. Our defense system consists of different units (immune cells) specialized to protect us from many intruders by using various tools. A unit described to be importantly involved in MS is called TH17 cell. It's best known tool, IL-17, mediates damage to the brain and facilitates immune cell entry into the brain. However, other tools besides IL-17 seem to be important in this disease.

Our results indicate that another tool used by these TH17 cells, IL-26, is involved in MS disease. Interestingly, it seems to inhibit immune cell entry into the brain instead of enhancing it. This suggest that IL-26 has a potential beneficial role in MS and might be a possible new therapy. However, this tool has been shown in other diseases to have detrimental effects by inducing inflammation. Therefore, it is necessary to further elucidate the mechanisms of IL-26 in MS. I propose to investigate the effect of IL-26 on other immune cells and study how this tool is involved in the entry of immune cells into the brain.